title: Efficacy of the American Heart Association/American Stroke Association guidelines for ultra-early, intentional antihypertensive therapy in intracerebral hemorrhage.
abstract: Whether the intentional antihypertensive therapy recommended by the American Heart Association/American Stroke Association (AHA/ASA) guidelines has clinical benefit for patients who have acute spontaneous intracerebral hemorrhage (ICH) has yet to be proven. We retrospectively reviewed the clinical charts of 175 patients with putaminal or thalamic ICH with acute hypertension to examine the correlation between the efficacy of antihypertensive therapy within 3 hours of onset, hematoma expansion (HE) after hospitalization and clinical outcome. The aim of the antihypertensive therapy was to achieve and maintain a systolic blood pressure of 120 mm Hg to 160 mm Hg until the second CT scan. The mean arterial pressure (MAP) after admission was the average MAP values measured every hour for the first 3 hours of hospitalization or until the second CT scan, if this was performed within the same timeframe. Thirty-two (18.3%) patients were found to have HE. Prior to the second CT scan, antihypertensive medications were administered to all patients without any major complications. A multiple logistic regression analysis revealed that a MAP of >110 mm Hg after admission was the only variable independently associated with HE (odds ratio [OR] = 3.455; 95% confidence interval [CI] = 1.510-8.412; p = 0.004). Modified Rankin Scale scores of < or = 3 on day 30 were significantly more common in those patients without HE (p = 0.002). Our findings suggest that there are clinical benefits, by the prevention of subsequent HE, in maintaining a MAP level lower than that recommended by the AHA/ASA (110 mm Hg) after hospitalization for patients who have ICH.
authors.affiliation: Department of Neurosurgery, Tokyo Medical and Dental University, 5-45, Yushima 1-cyome, Bunkyo-ku, Tokyo 113 8510, Japan. mutsu-ygc@umin.ac.jp
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fujii
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Tomita
authors.forename: Osamu
authors.initials: O
authors.lastname: Tone
authors.forename: Masashi
authors.initials: M
authors.lastname: Tamaki
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Takada
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Hokari
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nariai
authors.forename: Kikuo
authors.initials: K
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000572:American Heart Association; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006406:Hematoma / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D033182:Intention; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic / Q000592:standards*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D000959:Antihypertensive Agents